CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Gilead to Present 18-Month Anito-cel Trial Follow-Up Data in Multiple Myeloma at ASH 2026

By Public Technologies
  • Gilead Sciences and Kite will present 23 abstracts, including seven oral presentations, at ASH on December 12-15, 2026.
  • Updated pivotal Phase 2 anito-cel results will assess survival and safety in heavily pretreated patients with relapsed or refractory multiple myeloma.
  • The anito-cel study supports a U.S. marketing application under FDA review, with a decision target date of December 23, 2026.
  • Yescarta presentations will include five-year follow-up in first-line high-risk large B-cell lymphoma, alongside real-world treatment outcomes.
  • Investigational gamgertamig data will provide initial clinical findings on treatment response and durability in relapsed or refractory autoimmune cytopenias.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104303376) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk